リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line

Suprapto, Ratih Paramita Suzuki, Yoko Nagano, Tatsuya Hirata, Ken-ichi Emoto, Noriaki 神戸大学

2022.08.01

概要

Lung cancer is the leading cause of cancer-related deaths worldwide, and adenocarcinoma is the most common subtype of lung cancer. Endothelin-2 (ET-2) is expressed in the epithelium of alveoli, and its expression is increased in cancer. However, the role of ET-2 in lung adenocarcinoma remains unclear. This study aimed to investigate the pathophysiological functions of ET-2 in A549 human lung adenocarcinoma cells. We analyzed the expression of ET-2 mRNA in lung adenocarcinoma tissues compared with that in nontumor lung tissues using public online databases. The function of ET-2 in A549 cells was investigated using siRNA. ET-2 mRNA level was upregulated in lung adenocarcinoma tissues, and high ET-2 level was associated with poor overall survival in patients with lung adenocarcinoma. ET-2 silencing reduced the proliferation, migration, and invasion, and enhanced apoptosis in A549 cells. Mechanistically, ET-2 silencing reduced the expression levels of X-linked inhibitor of apoptosis and survivin, which are members of the inhibitor apoptosis protein family. In addition, silencing ET-2 inhibited epithelial–mesenchymal transition, which halted migration. Therefore, the specific targeting of ET-2 may be a potential treatment strategy for lung adenocarcinoma.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

Bratton, S.B., Lewis, J., Butterworth, M., Duckett, C.S., and Cohen, G.M. 2002. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis. Cell Death Differ. 9(9): 881–892. doi:10.1038/sj.cdd.4401069.

Cao, C., Mu, Y., Hallahan, D.E., and Lu, B. 2004. XIAP and survivin as thera- peutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene, 23(42): 7047–7052. doi:10.1038/sj.onc.1207929.

Chai, J., Shiozaki, E., Srinivasula, S.M., Wu, Q., Dataa, P., Alnemri, E.S., and Shi, Y. 2001. Structural basis of caspase-7 inhibition by XIAP. Cell, 104(5): 769–780.

Chang, I., Bramall, A.N., Baynash, A.G., Rattner, A., Rakheja, D. Post, M., et al. 2013. Endothelin-2 deficiency causes growth retardation, hy- pothermia, and emphysema in mice. J. Clin. Invest. 123(6): 2643– 2653. doi:10.1172/JCI66735.

Chang, Y.X., Lin, Y.F., Chen, C.L., Huang, M.S., Hsiao, M., and Liang, P.H. 2020. Chaperonin-containing TCP-1 promotes cancer chemoresistance and metastasis through the AKT–GSK3β–β-catenin and XIAP–survivin pathways. Cancers, 12(12): 1–25. doi:10.3390/ cancers12123865.

Dohi, T., Okada, K., Xia, F., Wilford, C.E., Samuel, T. Welsh, K., et al. 2004. An IAP–IAP complex inhibits apoptosis. J. Biol. Chem. 279(33): 34087– 34090. doi:10.1074/jbc.C400236200.

Fang, W., Che, X., Li, G., Wang, A., Wang, Y. Shi, X., et al. 2020. Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin–XIAP complex. J. Exp. Clin. Cancer Res. 39(1): 82. doi:10. 1186/s13046-020-01581-3.

Grimshaw, M.J., Naylor, S., and Balkwill, F.R. 2002. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol. Cancer Ther. 1(14): 1273–1281.

Grimshaw, M.J., Hagemann, T., Ayhan, A., Gillett, C.E., Binder, C., and Balkwill, F.R. 2004. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 64(7): 2461–2468.

Gyo˝ rffy, B. 2021. Survival analysis across the entire transcriptome identi- fies biomarkers with the highest prognostic power in breast cancer. Comput. Struct. Biotechnol. J. 19: 4101–4109. doi:10.1016/j.csbj.2021. 07.014.

Jin, Y., Lu, X., Wang, M., Zhao, X., and Xue, L. 2019. X-linked in- hibitor of apoptosis protein accelerates migration by inducing epithelial–mesenchymal transition through TGF-β signaling path- way in esophageal cancer cells. Cell Biosci. 9(1): 76. doi:10.1186/ s13578-019-0338-3.

Koong, A.C., Denko, N.C., Hudson, K.M., Schindler, C., Swiersz, L. Koch, C., et al. 2000. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60(4): 883–887.

Krepela, E., Dankova, P., Moravcikova, E., Krepelova, A., Prochazka, J. Cer- mak, J., et al. 2009. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int. J. Oncol. 35(6): 1449–1462. doi:10.3892/ijo_00000464.

Li, Y., Gao, W., Ma, Y., Zhu, G., Chen, F., and Qu, H. 2018. Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells. Oncol. Lett. 16(3): 3489–3498. doi:10.3892/ol.2018.9081.

Oberoi-Khanuja, T.K., Murali, A., and Rajalingam, K. 2013. IAPs on the move: role of inhibitors of apoptosis proteins in cell migration. Cell Death Dis. 4(9): e784 10.1038/cddis.2013.311.

Park, S.J., Yoon, B.H., Kim, S.K., and Kim, S.Y. (2019). GENT2: an updated gene expression database for normal and tumor tissues. BMC Med. Genomics, 12: 101. doi:10.1186/s12920-019-0514-7.

Pulido, I., Ollosi, S., Aparisi, S., Becker, J.H., Aliena-Valero, A. Benet, M., et al. 2020. Endothelin-1-mediated drug resistance in EGFR-mutant non-small cell lung carcinoma. Cancer Res. 80(19): 4224–4232. doi:10. 1158/0008-5472.CAN-20-0141.

Rosanò, L., and Bagnato, A. 2016. β-Arrestin1 at the cross-road of endothelin-1 signaling in cancer. In J. Exp. Clin. Cancer Res. 35: 121 10.1186/s13046-016-0401-4.

Sandhu, S., McNeil, C.M., LoRusso, P., Patel, M.R., Kabbarah, O. Li, C., et al. 2020. Phase I study of the anti-endothelin B receptor antibody–drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Invest. New Drugs, 38(3): 844–854. doi:10.1007/s10637-019-00832-1.

Sowa, T., Menju, T., Sonobe, M., Nakanishi, T., Shikuma, K. Imamura, N., et al. 2015. Association between epithelial–mesenchymal transition and cancer stemness and their effect on the prognosis of lung adeno- carcinoma. Cancer Med. 4(12): 1853–1862. doi:10.1002/cam4.556.

Srinivasula, S.M., Datta, P., Fan, X.J., Fernandes-Alnemri, T., Huang, Z., and Alnemri, E.S. 2000. Molecular determinants of the caspase- promoting activity of Smac/DIABLO and its role in the death recep- tor pathway. J. Biol. Chem. 275(46): 36152–36157. doi:10.1074/jbc. C000533200.

Sun, C., Cai, M., Meadows, R.P., Xu, N., Gunasekera, A.H. Herrmann, J., et al. 2000. NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 275(43): 33777– 33781. doi:10.1074/jbc.M006226200.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. 2021. Global cancer statistics 2020: GLOBOCAN esti- mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3): 209–249. doi:10.3322/caac.21660. Suzuki, Y., Nakabayashi, Y., Nakata, K., Reed, J.C., and Takahashi, R. 2001. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J. Biol. Chem. 276(29): 27058–27063. doi:10.1074/ jbc.M102415200.

Takahashi, R., Deveraux, Q., Tamm, I., Welsh, K., Assa-Munt, N., Salvesen, G.S., and Reed, J.C. 1998. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273(14): 7787–7790. doi:10.1074/ jbc.273.14.7787.

Tanese, K., Fukuma, M., Ishiko, A., and Sakamoto, M. 2010. Endothelin-2 is upregulated in basal cell carcinoma under control of hedgehog sig- naling pathway. Biochem. Biophys. Res. Commun. 391(1): 486–491. doi:10.1016/j.bbrc.2009.11.085.

Tang, Z., Kang, B., Li, C., Chen, T., and Zhang, Z. 2019. GEPIA2: an en- hanced web server for large-scale expression profiling and interac- tive analysis. Nucleic Acids Res. 47(W1): W556–W560. doi:10.1093/ nar/gkz430.

Tocci, P., Blandino, G., and Bagnato, A. 2021. YAP and endothelin-1 sig- naling: an emerging alliance in cancer. J. Exp. Clin. Cancer Res. 40: 1 27. doi:10.1186/s13046-021-01827-8.

Werner, T.A., Dizdar, L., Nolten, I., Riemer, J.C., Mersch, S. Schütte, S.C., et al. 2017. Survivin and XIAP——two potential biological targets in follicular thyroid carcinoma. Sci. Rep. 7(1): 11383. doi:10.1038/ s41598-017-11426-3.

Yi, X.P., Han, T., Li, Y.X., Long, X.Y., and Li, W.Z. 2015. Simultaneous si- lencing of XIAP and survivin causes partial mesenchymal–epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/ Akt pathway. Mol. Med. Rep. 12(1): 601–608. doi:10.3892/mmr.2015. 3380.

Zheng, M. 2016. Classification and pathology of lung cancer. Surg. Oncol. Clin. North Am. 25(3): 447–468. doi:10.1016/j.soc.2016.02.003.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る